Jazz Pharmaceuticals vs Royalty Pharma
JAZZ and RPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAZZ and RPRX compare
Royalty Pharma is the larger company, worth 2.8 times as much as Jazz Pharmaceuticals ($38.6B against $14.0B).
On earnings, Jazz Pharmaceuticals is cheaper: it trades at 14.8× trailing earnings, against 38.2× for Royalty Pharma.
Jazz Pharmaceuticals grew revenue faster over the last twelve months (12.6% versus 10.0% for Royalty Pharma).
Royalty Pharma keeps more of each dollar of sales as profit, with a net margin of 32.1% compared with 20.4% at Jazz Pharmaceuticals.
Royalty Pharma pays a dividend yielding 1.4%; Jazz Pharmaceuticals does not pay one.
Jazz Pharmaceuticals scores higher on the StockData Score (11 against 8 for Royalty Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAZZ | RPRX |
|---|---|---|
| Size and price | ||
| Market cap | $14.0B | $38.6B |
| Share price | $215.98 | $67.18 |
| Change, 1 year | 59.1% | 83.2% |
| Change, 5 years | 59.9% | 70.0% |
| Beta (5Y) | 0.55 | 0.41 |
| Employees | 2,890 | 100 |
| StockData Score | ||
| Total score | 11 (better) | 8 |
| Valuation score | 4 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 4 (better) | 2 |
| Health score | 2 | 2 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 14.8× (better) | 38.2× |
| P/S | 3.0× (better) | 15.2× |
| P/B | 2.9× | – |
| EV/EBITDA | 18.0× (better) | 32.9× |
| P/FCF | 8.8× | – |
| PEG | – | 0.24 |
| FCF yield | 11.4% | – |
| Fair value | $254.92 | $45.40 |
| Margin of safety | 15.3% (better) | −48.0% |
| Growth | ||
| Revenue growth (TTM) | 12.6% (better) | 10.0% |
| Revenue growth, 5Y average | 12.5% (better) | 2.3% |
| Net income growth (TTM) | – | −20.4% |
| EPS growth (TTM) | – | −19.3% |
| EPS growth, 5Y average | – | 6.2% |
| Profitability | ||
| Operating margin | 19.5% | 59.6% (better) |
| Net margin | 20.4% | 32.1% (better) |
| FCF margin | 34.6% | – |
| Return on equity | 22.1% | – |
| Return on invested capital | 12.1% | – |
| Financial health | ||
| Debt / equity | 0.91 | – |
| Net debt / EBITDA | 2.40 (better) | 5.37 |
| Interest coverage | – | 4.2× |
| Current ratio | 1.78 | 2.80 (better) |
| Altman Z-score | 2.35 | 2.93 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 1.4% |
| Buyback yield | – | 0.83% |
| Shareholder yield | 0.00% | 2.2% (better) |
| Ownership | ||
| Held by institutions | 99.2% | 63.8% |
| Held by insiders | 3.4% | 22.6% |
| Insider net buying, 12 months | −$68.0M (better) | −$92.6M |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 8.7% | 2.9% |
Go deeper
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
- RPRX stock overview
- RPRX income statement
- RPRX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.